Background: Secondary tracheal tumors arise from mural invasion by primary tumors in adjacent organs, metastatic lymph nodes or blood-born metastasis from distant sites. This systematic review aims to assess the presentation, management options, and clinical outcomes of these uncommon non-tracheal malignancies.
Introduction
Secondary tracheal tumors are defined as tumors in, but not of the trachea and comprise a wide spectrum of tumor histologies and stages. There are no populationbased data for these tumors, and in clinical practice these lesions are probably more common than primary neoplasms. A thoracic surgeon probably encounters tracheal obstruction by metastatic lymph nodes more often than invasion by adjacent primary tumors. Since natural history and prognosis are related to the tumor of origin, their management and prognosis may differ considerably from primary tracheal neoplasms; a correct diagnosis with attribution to the original tumor is therefore important.
Tracheal invasion by metastasis may further be categorized as metachronous when the diagnosis is made after a diseasefree interval, in contrast to synchronous diagnosis when primary malignancy coincides with tracheal invasion.
Secondary tracheal tumors may arise from hematogenous or lymphatic sites of metastasis, or by direct extension from adjacent structures including thyroid or esophagus.
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Ann Cardiothorac Surg 2018;7(2):183-196 www.annalscts.com A useful and detailed classification of tracheobronchial metastases was proposed by Kiryu and associates based on the relationship of the primary tumor to the trachea (1) . Type 1 tumors are direct metastases to the bronchus; type 2, invasion by an adjacent parenchymal lesion; type 3, invasion by lymph nodes; and type 4, peripheral lesion extending proximally along the airway wall. Most of the studies that we reviewed below reported type 1 tumors from extrapulmonary sites or type 2 tumors from the thyroid. We suspect, however, that invasion by adjacent lymph nodes metastatic from lung, esophageal, head and neck or other cancer is the most frequent form of metastasis; this type would be less represented in reports because the trachea is not the sole focus of attention in progressive disease and the survival of patients after diagnosis is short.
The true incidence of secondary tracheal tumors is unknown. One of the earliest cases of endotracheal metastasis was reported in 1954 in a case of colon cancer metastatic to the trachea (2) . Existing epidemiological studies mainly focus on endobronchial metastases and contain different exclusion criteria. In an autopsy study of 1,000 consecutive cases of malignant neoplasms of epithelial origin from 1943 to 1947, six endotracheal metastases originated from primary sites of lung (3), larynx (1) and breast (1); however, this study excluded cases of direct extension to adjacent organs (4) . Another study analyzing 1,359 consecutive autopsies from 1968 to 1971 found a 2% incidence of endobronchial metastases and 0.8% of endotracheal metastasis from primary thyroid cancer (1) and melanoma (1) ; cases of lymphoma, central nervous system tumors and primary lung neoplasms were excluded (3) . A literature review from 1966 to 2002 found 204 confirmed cases of endobronchial metastases from extrapulmonary solid tumors, while 4% were located in the trachea (5) .
We are unaware of any prior collective analysis of secondary tracheal tumors. In this study, we conduct a systematic review of secondary tracheal tumors based on studies available in the MEDLINE database to analyze the evolution of practice patterns and assess the relative merits of nonoperative, bronchoscopic and surgical therapy. The aim of this study is to provide a guide to multidisciplinary management of patients presenting with airway obstruction from secondary tracheal tumors.
Methods

Literature search strategy
A systematic review was performed. MEDLINE was searched for original published studies using the terms: "tracheal metastasis" OR "secondary tracheal tumors" OR "endotracheal metastasis" OR "tracheobronchial tumors".
Eligibility criteria
Studies eligible for this systematic review included patients with metastatic disease to the trachea or primary tumors secondarily involving the trachea. We included individual case reports, single institutional case series and multiinstitutional case series while excluding reviews, editorials, expert opinions and studies that lacked abstracts. Several reports collected primary and secondary tracheal tumors, or tracheal and bronchial tumors; the data regarding secondary tracheal tumors were specifically extracted and included in this study. For repeated publications reporting similar patients from the same institution, the most recent data set was included [e.g., (6) (7) (8) ].
Data extraction and critical appraisal
One reviewer (ML Madariaga) reviewed each included study and extracted data from text, tables and figures. Another author reviewed the extracted data (HA Gaissert). All data were entered into a standardized database.
Statistical analysis
Results will be presented as means and ranges where applicable. Kaplan-Meier survival analysis was performed for treatment groups of ≥10 patients derived from individual studies.
Outcome measures
The primary endpoints included symptom relief, overall survival, disease recurrence and 30-day postoperative or post-procedure complications. Secondary endpoints included tumor histology, location of tracheal tumor, and treatment.
Surgical technique
Techniques to resect tracheal invasion were classified as window resection (resection of the anterior tracheal wall only), shave resection (partial thickness resection of the trachea), segmental tracheal resection (circumferential fullthickness resection), exenteration (resection of trachea, esophagus, larynx and other cervicomediastinal structures), and debulking (less than complete resection), the latter by endoscopic or open methods.
Results
Quantity of evidence
After applying our search criteria, 2,866 studies were identified. Manual evaluation of abstracts and full-length articles identified 160 relevant publications. There were 64 individual case reports and 96 case series (consisting of more than one case). Of the 96 case series, 17 series contained enough details to extract individual patient data; these 110 patients were analyzed with the individual case reports (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) . Forty-five case series reported exclusively on tracheal invasion by thyroid cancer (Table S1 ). A total number of 2,242 patients were included in this study, 174 patients in individual case reports and 2,068 patients in case series.
Quality of evidence
All were retrospective, observational series, and there were no randomized controlled or prospective trials. Thirty retrospective case series included bronchial as well as tracheal lesions, or primary in addition to secondary tracheal tumors, but only provided outcome measures based on the general study population (Table S1 ). Where possible, data relevant to secondary tracheal tumors were specifically extracted. However, to facilitate interpretation of the general outcome measures in case series, the number of patients with tracheal tumors was compared with the total number of patients in the study (Tables S2,S3 ). Data unavailable for extraction were left blank in the accompanying tables.
Patient demographics
Among 2,242 patients, mean age of patients was 58.5 years and 58.4% were female. The most common histologic types were well-differentiated thyroid cancer (74%), unspecified esophageal cancer (5.93%), and squamous cell carcinoma of the lung (2.77%) ( Table 1 ). In 9.5% of patients, the tumor was not otherwise specified or there was a mix of tumor histology not defined for each patient ( Table 1) .
Symptoms
The presence of symptoms was recorded for 50.4% (n=1,130) of included cases ( Table 2) . Among 95.2% of patients, the leading symptoms were dyspnea (31.8%), neck mass (19.5%), voice change or hoarseness (15.0%), and hemoptysis (13.7%), while 4.8% were asymptomatic.
Concurrent metastases
Among case series of well-differentiated thyroid cancer, lung metastases were present in 13.8% (range, 6.5% to 20.0%) of patients at the time of or prior to diagnosis (7, (25) (26) (27) (28) (29) (30) (31) and esophageal involvement in 29.0% (range, 4.9% to 62.0%) (6, 25, 29, (31) (32) (33) (34) (35) (36) . Lung metastases were also present at or prior to secondary tracheal tumor diagnosis in patients with renal cell carcinoma (22%), rectal cancer (85%), melanoma (16.7%), esophageal cancer (3%), colon cancer (33.3%), carcinoma with thymus-like differentiation (CASTLE; 12.5%) and breast cancer (40%) ( Table S1 ). Individual patients with liposarcoma and hepatocellular carcinoma also had lung metastasis (37, 38) .
Interval between initial diagnosis and secondary tracheal tumor presentation
The time interval between initial tumor diagnosis and secondary tracheal involvement was known in 622 (27.7%) patients, as shown in Table 3 . Two thirds of patients presented with delay after diagnosis of the primary tumor. Patients with renal cell carcinoma had the longest median metachronous interval (90.0 months), followed by ovarian (84.0 months) and breast cancer (72.0 months). The shortest median metachronous interval was observed in squamous cell carcinoma of the lung (14.5 months), esthesioneuroblastoma (15.0 months) and adenocarcinoma of the lung (16.5 months). In one study collecting data from patients with various secondary tracheal tumors, the median metachronous interval was 7.3 months (121). (Table S2 ).
Assessment of treatment
In individual case reports, data regarding treatment and outcome was available in 170 patients. The median followup interval was 21 months (range, 0.03-183 months). Treatment was characterized as bronchoscopic alone in 16.5%, bronchoscopy with chemotherapy/radiation in 6.5%, surgical management alone in 32.9%, surgical management with chemotherapy/radiation in 28.3%, combined surgical and bronchoscopic management in 2.4%, chemotherapy/radiation alone in 11% and in 2.4%, a combination of resection, bronchoscopy and chemotherapy/radiation. Surgical therapy for tracheal invasion included circumferential resection in 65%, exenteration in 14.2%, window resection in 5.4%, shave resection in 2.7%, and debulking in 2.7%. The average length of resected circumferential trachea measured 3.7 rings or 3.8 cm ( Table S3) .
We are not aware of any combined resections of trachea and the entire esophagus with successful reconstruction of tracheal continuity. In the literature of invasive thyroid cancer, there was one case of laryngotracheoesophagectomy with reconstruction of the digestive tract with a forearm free flap (109) . There were 28 cases of circumferential tracheal and partial-thickness or partial-circumference esophageal resection with reconstruction (6, 8, 10, 25, 29) and in addition two cases of combined partial resection of trachea and esophagus (25) . One series reported concomitant unspecified esophageal resection with tracheal shave (n=5), tracheal window resection (n=2) and circumferential tracheal resection with reconstruction (n=1) (31) . Two series of aerodigestive tract invasion by thyroid cancer reported patients who underwent partial to circumferential tracheal and esophageal resections, but did not specify how many patients had concomitant resections (33, 36) . There was one patient with esophageal cancer who underwent tangential tracheal resection, spiral tracheoplasty and esophagectomy (19) and two patients with esophageal cancer who underwent partial esophagectomy with partial tracheal resection and muscle flap reconstruction (15) .
Six case series of thyroid cancer invading the trachea directly analyzed survival associated with different treatment options. One study from China with 156 patients with thyroid cancer showed that 5-year survival was 100% with 0 cancer recurrence after circumferential resection compared to 5-year survival of <10% with 54% cancer recurrence after tracheal shaving (29) ; circumferential tracheal resection showed improved survival over tracheal shaving in other studies as well (31) . However, other studies did not demonstrate significant difference in survival outcomes between tracheal shave and circumferential resection (122, 123) . In one study from Japan containing 114 patients, those undergoing shave resection had better 5-year survival (99%) than those undergoing circumferential resection (71%) (124) ; this result was also seen in a study of 65 patients from Korea (35) ; there was no analysis of survival beyond 5 years in these slow-growing tumors.
Assessment of complications
Data regarding complications after treatment were available in 54.4% of patients from case series and are detailed in Table 4 and Tables S2,S3. The rate of complications ranged from 12.5% to 16.7% for bronchoscopic management with chemotherapy/radiation, 0.0% to 58.0% for bronchoscopy alone, 0.0% to 78.0% for resection alone and 0.0% to 61.0% for surgery with chemotherapy/radiation.
The most common complications after bronchoscopic intervention was bleeding (range, 17-33%), formation of granulation tissue after stent insertion (range, 17-58%), retained sputum (range, 11-33%) and stent migration (8%) ( Table 4) . Death during hospitalization occurred in 0.01% to 0.04%.
Following resection, the most common complications were anastomotic leak (range, 0.04-23.8%), chyle leak (range, 4.3-22%), new recurrent laryngeal nerve paralysis (range, 0.04-55%), esophageal fistula (5-6%), unplanned permanent tracheostomy (range, 4.3-50%), respiratory failure or prolonged intubation (10%), tracheal stenosis (5%) and wound infection (range, 1.4-11%). In one study of thyroidectomy, lymph node dissection and shave resection of the trachea with radioactive iodine and selected adjuvant external beam radiation, all patients experienced dysphagia after radiation (125) . Hospital mortality ranged from 0.02% to 1.4% in this group. Data on complications were available for 70% of individual case reports (121 of 174 patients). There were no complications in 70% of all cases with available data. The most frequent complications were anastomotic leak in 9.0%, tracheal stenosis in 3.3% and unplanned permanent tracheostomy in 3.3%. Additional complications included respiratory failure or prolonged intubation in 2.5%, new recurrent laryngeal nerve permanent paralysis in 2.5%, esophageal leak or fistula in 2.4%, dysphagia in 2.5% and hospital death in 2.5%.
Assessment of survival
In our review of case series, 95% of patients had data regarding survival outcomes as shown in Table S2 . Following surgical therapy, 5-year survival ranged from <10% to 100% and 10-year survival ranged from 15% to 90%. Reported median survival after bronchoscopic management ranged from 0.3 to 75.0 months, whereas median survival in the surgery treatment group ranged from 3 to 207 months. In the case series, median survival in patients with non-thyroid malignancy ranged from 1 to 18 months and in thyroid malignancy from 8.0 to 112.8 months. Median 5-year survival in patients with thyroid malignancy was 74.2% [range, <10% after shave resection (29) to 100%]. The 174 patients in individual case reports were grouped by treatment modality, cancer histology and available survival outcomes data to conduct Kaplan-Meier survival analysis (Table S3) . Overall 5-year survival was 80% after resection alone (n=47), 75% after resection with chemotherapy/radiation (n=44), 25% after bronchoscopic intervention with or without stent placement (n=19) and less than 20% after bronchoscopy with chemotherapy/radiation (n=10). Overall 5-year survival was 42% in patients with non-thyroid and 78% in thyroid malignancy; overall 10-year survival was 42% in patients with non-thyroid and 55% in thyroid cancer.
Assessment of recurrence
Data on recurrence were extracted from 13 case series identified for collective analysis (7, 17, 27, 29, 33, 35, 73, 124, 126, (135) (136) (137) (138) ) and nine individual case reports (14, 15, 17, 44, 56, 61, 81, 98, 139) and are listed in Table S4 . The disease-free interval ranged from 1 to 58 months. Among patients with thyroid cancer who underwent bronchoscopic intervention, the incidence of recurrence ranged from 17% to 82%. Recurrence after segmental tracheal resection for thyroid cancer ranged from 0% to 34% and after tracheal shave resection from 4.7% to 54%. One study comparing shave and segmental tracheal resection for thyroid cancer found the local recurrence higher after shave resection [54% versus 0%, (29) ]. Data on recurrence in patients with other cancer histology were too few to draw meaningful conclusions.
Discussion
Few individual centers amass a meaningful clinical experience in the management of tracheal tumors, and far fewer yet in secondary tracheal malignancy. The extraction of information from data useful to the clinical surgeon is therefore difficult and requires critical reading between the lines. Case reports often emphasize perceived successes, while palliative intervention in patients with advanced, progressive malignant disease is probably underreported. There are, however, several principal findings and conclusions we consider central to the understanding of secondary tracheal malignancy.
(I) The distinction between invasion by a primary tumor of a structure adjacent to the trachea and a lymphatic or hematogenous metastasis is important for treatment and the assessment of prognosis;
(II) Obtaining the histologic diagnosis is valuable even after the distinction outlined by point I) is made, since more than one tumor type may arise from organs or lymph nodes adjacent to the trachea; (III) Even when considering the guarded prognosis of most unreported secondary tracheal malignancies, segmental tracheal resection is successful in patients who are carefully selected for favorable histology and limited airway involvement; (IV) While secondary tracheal tumors often require the coordinated deployment of multiple modalities, a tracheal surgeon experienced in segmental resection is a key member of this group; (V) Oncologically doubtful interventions on the trachea, specifically shave and window resections, have no proven value in treatment with curative intent. Neither windows nor shaves permit the reliable assessment of margins and persist in use only because the consequence of incomplete resection is not discovered for many months or years. Since the tumors often occur in younger patients, observation of survival should extend to 20 or even 30 years to capture meaningful adverse events; (VI) Cervical exenteration involves resection of both trachea and esophagus, but does not result in endto-end tracheal reconstruction. An important consequence of esophageal resection is the loss of tracheal blood supply as the vascular arcades on either side are disrupted. Even though any resection of the esophagus above the carina inevitably renders the trachea ischemic, no sequelae occur in absence of a tracheal anastomosis. The addition of a tracheal anastomosis to complete esophageal resection poses a high risk of failure even with only modest tension due to ischemia. The major limitation of this study is its reliance on case studies or case series that have incomplete or heterogeneous information. Most studies examined patients with endobronchial metastases, where cases of endotracheal metastases are few; other studies presented outcomes based on mixed tumor histology of secondary tracheal tumors. In conclusion, this comprehensive systematic review of secondary tracheal tumors highlights common presentations, modes of treatment and general outcomes. Patients with secondary tracheal tumors should be assessed for overall prognosis and impediments to quality of life. An individualized treatment approach involving surgical, bronchoscopic and medical therapies can then be utilized to optimize clinical outcomes. 
Window, resection of anterior tracheal wall; shave, shave resection of trachea (partial thickness); wedge, wedge resection of trachea (full-thickness); resection, circumferential trachea resection (extent of tracheal resection if known); exenteration: trachea and other structures (not including larynx or thyroid); chemo, chemotherapy; LND, lymph node dissection; RAI, radioactive iodine; RLN, recurrent laryngeal nerve; XRT, radiation therapy; PTX, pneumothorax; PNA, pneumonia; APC, argon plasma coagulation; TEF, tracheoesophageal fistula; PEG, percutaneous endoscopic gastrostomy tube. Window, resection of anterior tracheal wall; shave, shave resection of trachea (partial thickness); wedge, wedge resection of trachea (full-thickness); resection, circumferential trachea resection (extent of tracheal resection if known); exenteration, trachea and other structures (not including larynx or thyroid); LND, lymph node dissection; RAI, radioactive iodine; RLN, recurrent laryngeal nerve; XRT, radiation therapy; ARDS, acute respiratory distress syndrome. 
